Impact of renal insufficiency on safety and efficacy of drug-eluting stents compared to bare-metal stents at 6 years

Catheterization and Cardiovascular Interventions

Volumn 80, Issue 1, 2012, Pages 18-26

  Simsek, Cihan ^a   Magro, Michael ^a   Boersma, Eric ^a   Onuma, Yoshinobu ^a   Nauta, Sjoerd ^a   Valstar, Gideon ^a   Van Geuns, Robert Jan ^a   Van Der Giessen, Willem ^a   Van Domburg, Ron ^a   Serruys, Patrick ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

kidney function; percutaneous coronary intervention; stents

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; RAPAMYCIN;

ADULT; ARTICLE; BARE METAL STENT; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE CLEARANCE; DEVICE SAFETY; DRUG ELUTING STENT; FEMALE; HAZARD RATIO; HEART INFARCTION; HUMAN; KAPLAN MEIER METHOD; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODEL; REVASCULARIZATION; STENT THROMBOSIS;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; CREATININE; DRUG-ELUTING STENTS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY; MALE; METALS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; PACLITAXEL; PATIENT SAFETY; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; REGISTRIES; RENAL INSUFFICIENCY; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SIROLIMUS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862882941     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.23199     Document Type: Article

References (25)

1. Best PJ, Lennon R, Ting HH, et al. The impact of renal insuffiency on clinical outcomes in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2002; 39: 1113-1119. (Pubitemid 34267412)
2. Rubenstein MH, Harrell LC, Sheynberg BV, et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000; 102: 2966-2972.
3. Cardarelli F, Bellasi A, Veledar E, et al. Impact of race and chronic kidney disease on 1-year outcome in patients undergoing percutaneous coronary interventions: A single tertiary center experience. Am Heart J 2008; 155: 1027-1032.
4. Garg P, Charytan DM, Novack L, et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after sirolimus-eluting and bare metal stent implantation (from the SIRIUS trials). Am J Cardiol 2010; 106: 1436-1442.
5. Lemos PA, Arampatzis CA, Hoye A, et al. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am J Cardiol 2005; 95: 167-172. (Pubitemid 40092079)
6. Halkin A, Mehran R, Casey CW, et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: Results from the TAXUS-IV trial. Am Heart J 2005; 150: 1163-1170. (Pubitemid 41773517)
7. Daemen J, Kukreja N, van Twisk PH, et al. Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry. Am J Cardiol 2008; 101: 1105-1111.
8. Daemen J, Tsuchida K, Stefanini GG, et al. Two-year clinical follow-up of the unrestricted use of the paclitaxel-eluting stents compared to the sirolimus-eluting stent as part of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. EuroIntervention 2006; 2: 330-333.
9. Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: Five-year results of the RAVEL trial. J Am Coll Cardiol 2007; 50: 1299-1304. (Pubitemid 47454687)
10. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323. (Pubitemid 37186209)
11. Ellis SG, Stone GW, Cox DA, et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv 2009; 2: 1248-1259.
12. Silber S, Colombo A, Banning AP, et al. Final 5-year results of the TAXUS II trial: A randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation 2009; 120: 1498-1504.
13. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008. (Pubitemid 46376800)
14. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004; 109: 190-195. (Pubitemid 38114138)
15. Ong AT, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population: One-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005; 45: 1135-1141. (Pubitemid 40432449)
16. Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62: 1402-1407.
17. Gesquiere L, Loreau N, Minnich A, et al. Oxidative stress leads to cholesterol accumulation in vascular smooth muscle cells. Free Radic Biol Med 1999; 27: 134-145. (Pubitemid 29353094)
18. Manske CL, Wang Y, Rector T, et al. Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. Lancet 1992; 340: 998-1002.
19. Simsek C, Magro M, Boersma E, et al. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: An analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries. JACC Cardiovasc Interv 2010; 3: 1051-1058.
20. Ford I, Bezlyak V, Stott DJ, et al. Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: Secondary analysis. PLoS Med 2009; 6: e16.
21. Rifkin DE, Shlipak MG, Katz R, et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 2008; 168: 2212-2218.
22. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after succesful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130. (Pubitemid 40617065)
23. de la Torre-Hernandez JM, Alfonso F, Hernandez F, et al. Drug-eluting stent thrombosis. Results from the multicenter Spanish registry ESTROFA. J Am Coll Cardiol 2008; 51: 986-990.
24. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98: 352-356.
25. Lambert ND, Sacrinty MT, Ketch TR, et al. Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction. Am Heart J 2009; 157: 688-694.